Related Experiment Video
Updated: Oct 24, 2025
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
Circulating tumour DNA for clinicians: current and future clinical applications.
M K Thompson1, D Gale2, J D Brenton1
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 0RE, UK; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, CB2 0RE, UK.
Circulating tumor DNA (ctDNA) analysis offers advanced cancer care, from precision treatment to early detection. Understanding ctDNA biology and technology is crucial for its clinical integration and impact on patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Circulating tumor DNA (ctDNA) is a non-invasive biomarker with growing clinical significance.
- Advances in detection technology have significantly enhanced ctDNA sensitivity over the past decade.
Purpose of the Study:
- To provide clinicians with a foundational understanding of ctDNA biology and technology.
- To review current clinical applications and future directions of ctDNA in cancer care.
Main Methods:
- Overview of ctDNA detection technologies, including whole-genome sequencing (WGS), targeted gene panels, and methylation analysis.
- Synthesis of recent clinical trial evidence for ctDNA in various cancer care settings.
Main Results:
- ctDNA facilitates precision treatment for advanced cancers and aids in disease monitoring.
- ctDNA shows promise in improving adjuvant treatment strategies and enabling early cancer detection through screening.
Conclusions:
- ctDNA is poised to significantly impact radiological practice and patient management.
- Further research is necessary to fully integrate ctDNA into routine clinical workflows and applications.
